Mobility Program Clinical Research Unit, Li Ka Shing Knowledge Institute, St Michael's Hospital, 30 Bond St., Toronto, ON, M5B 1W8, Canada,
Osteoporos Int. 2014 Jan;25(1):289-96. doi: 10.1007/s00198-013-2430-6. Epub 2013 Jun 21.
Potential mediating factors in the pathway to initiation of osteoporosis treatment following a fragility fracture were evaluated. Patients' perceived need for treatment, mediated by their perception of bone density test results, was central to treatment initiation. Interventions focusing on patients' perceptions of need and test results may improve treatment rates.
We tested a hypothesized pathway to osteoporosis (OP) pharmacotherapy initiation in fragility fracture patients. We hypothesized that bone mineral density (BMD) testing is strongly associated with treatment initiation and perception of BMD test results would inform patients' perceived need for treatment, which would mediate the effect between BMD testing and treatment initiation.
A longitudinal cohort study followed patients, ≥50 years of age, screened for fragility fracture in 31 fracture clinics in Ontario, Canada who had no prior diagnosis of or treatment for OP. At screening, OP risk factors, baseline-patient perception of OP risk, OP knowledge, and perceived benefits of medication were reported by patients. Patients were followed up within 6 months of fracture to determine BMD testing and prescription of and adherence to first-line OP pharmacotherapy. Structural equation modeling tested the hypothesized pathway. Significance and magnitude of the coefficients and indicators of overall model fit were used to test our model.
The direct path from BMD testing to OP treatment initiation was non-significant. The pathway to treatment initiation was mediated by patients' perception of their need, which was influenced by their self-reported BMD results. Baseline fracture risk factors, knowledge of OP, and perceived benefits of treatment-predicted patient-perceived need for treatment at follow-up and initiation of OP treatment.
Patient perceptions were central factors in the path to initiation of OP pharmacotherapy. Interventions to facilitate accurate patient perceptions of BMD test results and OP risk status could prove helpful in improving OP treatment initiation.
评估脆性骨折后骨质疏松症(OP)治疗起始的潜在中介因素。患者对治疗的需求是由其对骨密度(BMD)检测结果的感知所介导的,这是治疗起始的关键因素。关注患者对治疗需求和检测结果的感知的干预措施可能会提高治疗率。
我们测试了一个关于脆性骨折患者发生骨质疏松症药物治疗起始的假设路径。我们假设 BMD 检测与治疗起始密切相关,而对 BMD 检测结果的感知将告知患者对治疗的需求,这将在 BMD 检测与治疗起始之间起到中介作用。
一项纵向队列研究对在加拿大安大略省 31 个骨折诊所筛选出的≥50 岁的脆性骨折患者进行了随访,这些患者以前没有骨质疏松症的诊断或治疗。在筛选时,患者报告了骨质疏松症风险因素、基线时患者对骨质疏松症风险的感知、骨质疏松症知识以及对药物治疗益处的感知。在骨折后 6 个月内对患者进行随访,以确定 BMD 检测以及一线骨质疏松症药物治疗的处方和依从情况。结构方程模型检验了假设的路径。使用系数和整体模型拟合指标的显著性和大小来检验我们的模型。
从 BMD 检测到 OP 治疗起始的直接路径没有统计学意义。治疗起始的途径是由患者对自身治疗需求的感知所介导的,而这又受到其自我报告的 BMD 结果的影响。基线骨折风险因素、对骨质疏松症的认识以及对治疗益处的感知预测了患者在随访时对治疗需求的感知以及对 OP 治疗的起始。
患者感知是启动 OP 药物治疗的核心因素。促进患者对 BMD 检测结果和 OP 风险状况的准确感知的干预措施可能有助于改善 OP 治疗的起始。